Brain Repair Protocol
80
التعاون
3
10,850
advanced
May 17, 2026
نظرة عامة
The Brain Repair Protocol represents the most aggressive peptide approach to neuroregeneration, combining a potent hepatocyte growth factor (HGF) mimetic with established neuroprotective peptides. Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is a modified angiotensin IV analog that was discovered at Washington State University to be approximately 10 million times more potent than BDNF at promoting neuronal connectivity. It acts as an HGF/c-Met receptor agonist, stimulating the formation of new synaptic connections (synaptogenesis) and promoting the survival of existing neurons. In animal models of cognitive impairment, Dihexa restored learning and memory to levels comparable to young control animals. Semax provides complementary neuroprotection through BDNF/NGF upregulation and modulation of the melanocortin system in the brain. Its effects on neuroplasticity — the brain''s ability to form new neural pathways — make it an ideal companion to Dihexa''s synaptogenic activity. While Dihexa builds new connections, Semax ensures the molecular environment (neurotrophic factors, receptor density) supports the survival and strengthening of those connections through long-term potentiation mechanisms. BPC-157 is included for its documented neuroprotective effects, including modulation of the dopaminergic system, protection against excitotoxic damage (NMDA receptor modulation), and promotion of nerve growth factor expression. In animal models, BPC-157 has shown efficacy against traumatic brain injury, counteracted the effects of neurotoxins, and promoted peripheral nerve regeneration. The three-peptide combination addresses neuroregeneration from multiple angles: structural connectivity (Dihexa), neurotrophic environment (Semax), and neuroprotection/repair (BPC-157). This stack is classified as advanced and researcher-only due to Dihexa''s extreme potency, complete lack of human safety data, and theoretical concerns about its proliferative potential. It is not recommended without medical supervision and thorough risk assessment.
بروتوكول الجرعة
10,000 mcg
كل جرعة
600 mcg
كل جرعة
250 mcg
كل جرعة
الأهداف والدليل
تحذيرات
- Dihexa is a potent HGF mimetic with NO human trials. Extremely experimental. Semax has Russian approval. BPC-157 was removed from FDA Category 2 (April 2026) but remains under PCAC review — not legal to compound yet. This stack is for researchers only.
Comments
Sign in to join the discussion
تحذير: هذا الكود مقدم من قبل المجتمع ويهدف لغرض البحث فقط. لا يتحقق Peptide Contacts من سلامة أو فعالية الأكواد المقدمة. استشر محترف صحي مؤهل قبل استخدام أي بروتوكول بروتيني.